Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 6 for:    Intrexon

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03126864
Recruitment Status : Recruiting
First Posted : April 24, 2017
Last Update Posted : October 8, 2018
Sponsor:
Collaborators:
Intrexon Corporation
Ziopharm
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 2021
  Estimated Study Completion Date : August 2021